SRSeyyed Mobin Rahimnia

Seyyed Mobin Rahimnia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Seyyed Mobin Rahimnia has a total of 75 co-authors. Here are the top co-authors by number of shared publications:

  • Seyyed Mohammad Hassan Hashemi

    Food Health Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran

    6 shared publications
  • Jafar Akbari

    Department of pharmaceutics, faculty of pharmacy, Mazandaran university of medical sciences

    5 shared publications
  • Katayoun Morteza-Semnani

    Department of Medicinal Chemistry, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran

    4 shared publications
  • Majid Saeedi

    Department of Pharmaceutics, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran

    4 shared publications
  • Majid Saeedi

    Department of Pharmaceutics, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran; Pharmaceutical Sciences Research Centre, Haemoglobinopathy Institute, Mazandaran University of Medical Sciences, Sari, Iran

    3 shared publications
  • Abbas Raeisabadi

    Student Research Committee Mazandaran University of Medical Sciences Sari Iran

    2 shared publications

Latest Publications

  • Arbutin-Loaded Solid Lipid Nanoparticles as Safe and Potent Green Biodegradable Nano systems for Melanin Synthesis Inhibition, Anti-Tyrosinase, and Antioxidant Effects

    by Mahmoud Omidi, Nikoo Ghasabeh Siahkal-Mahaleh, Seyyed Mobin Rahimnia, Hamed Rahmanshenas, Manouchehr Jandaghi, Mojtaba Shabani-Borujeni, Esmaeil Mohammadian, Seyyed Mohammad Hassan Hashemi


  • Open Access

    Efficacy Evaluation of Luliconazole‐Loaded Nanostructured Lipid Carriers in Treatment‐Resistant Dermatophytosis: A Randomized Clinical Trial

    by Robab Ebrahimi Barogh, Seyed Ali Jeddi, Ghasem Rahmatpour Rokni, Hossein Mohammad Taghi Fam, Abbas Raeisabadi, Zahra Yahyazadeh, Seyyed Mobin Rahimnia, Pedram Ebrahimnejad, Eisa Nazar, Nasim Gholizadeh, et al.

    Background: Dermatophytosis is a common superficial fungal infection that is increasingly complicated by terbinafine (TRB)‐resistant strains, especially Trichophyton indotineae . Conventional antifungals often show limited efficacy against resistant isolates, highlighting the need for novel treatments. This study evaluated the efficacy and safety of nanostructured lipid carrier–loaded luliconazole (NLC‐LCZ) gel in TRB‐resistant dermatophytosis. Materials and Methods: In a randomized, clinical trial conducted at Touba Specialty Clinic, Sari, Iran, forty‐eight adults with confirmed TRB‐resistant dermatophytosis were assigned to oral itraconazole (ITZ), topical luliconazole, NLC‐LCZ gel, or ITZ + NLC‐LCZ gel for 4 weeks ( n = 12 each). The primary endpoint was complete recovery (clinical and mycological), while secondary endpoints included lesion size, itch, inflammation, Dermatology Life Quality Index (DLQI), and safety. Results: Complete recovery occurred in 83.3% of ITZ + NLC‐LCZ, 75% of NLC‐LCZ, 58.3% of LCZ, and 0% of ITZ alone. LCZ and NLC‐LCZ had lower MIC 50 / MIC 90 values (0.016 μg/mL) compared with ITZ (MIC 90 : 8 μg/mL) and TRB (MIC 90 : 4 μg/mL). DLQI improved most in NLC‐LCZ (score: 2) and ITZ + NLC‐LCZ (score: 3) groups ( p < 0.001). Adverse events were mild and did not require discontinuation. Conclusions: These findings indicate that NLC‐LCZ enhanced antifungal efficacy and quality of life in TRB‐resistant dermatophytosis, and that combination therapy with ITZ + NLC‐LCZ yielded the highest recovery, representing a promising strategy against resistant infections.

  • Green and biocompatible formulation of arbutin encapsulated alginate nanoparticle: improved cytotoxicity against melanoma cancer and potent inhibition of melanin biosynthesis and L-DOPA auto-oxidation

    by Mahmoud Omidi, Nikoo Ghasabeh Siahkal-Mahaleh, Seyyed Mobin Rahimnia, Ali Raofi, Manouchehr Jandaghi, Mojtaba Shabani-Borujeni, Esmaeil Mohammadian, Seyyed Mohammad Hassan Hashemi

    The elevated melanin production within the skin results in a distressing pigmentation disorder called melanoma. This underscores the importance of developing effective therapeutic approaches, such as nano-delivery systems. The primary objective of this research was to create alginate (AL) nanoparticle (NP) in gel dosage for improving targeting of arbutin (ARB) as a lightening substance to cure and manage melanoma cancer. Ionic gelation and ultrasonication method were employed to prepare ARB-AL-NP followed by In-vitro assessment of the NP. Outcomes noticed that the optimum ARB-AL-NP were in the size of 252.333 ± 11.873 nm with zeta potential -14.766 ± 0.862, greater encapsulation 89.831 ± 1.081%, and exhibited sustained release of ARB over 6 h (56%). In vitro MTT analysis confirmed that the optimum formulation had higher cell survival on the HFF cell line than kojic-acid and ARB, however, it showed a greater cytotoxic effect on the B16f10 cell line than other groups. Besides, ARB-AL-NP was established to obstruct melanogenesis to a superior level than kojic-acid and ARB and considerably suppress L-dopa auto-oxidation contrasted to kojic-acid and ARB). The outcomes of this assessment confirmed that the ARB-AL-NP could potentially serve as a prospective nanocarrier for ARB cutaneous application, thus unveiling novel approaches for addressing melanoma complaints.


  • Gene and cellular assessment of wound healing with a novel natural cocktail gel dressing: A new method for quantitative wound closure time assessment

    by Reza Eshaghi-Gorji, Reyhaneh Nassiri Mansour, Fatemeh Soleimanifar, Majid Saeedi, Emran Habibi, Keyvan Mehdipour-Chari, SeyedehElnaz Enderami, Fereshteh Talebpour Amiri, Seyyed Mobin Rahimnia, Mansoureh Mirzaei, et al.

  • Open Access

    The Therapeutic Effects of a Bentonite‐Based Facial Mask With Alcea sulphurea Extract on Acne Severity and Patient Experience: Add‐On Randomized Controlled Clinical Trial

    by Sara Salimi, Moloud Fakhri, Majid Saeedi, Seyyed Mobin Rahimnia, Armaghan Kazeminejad, Mahmood Moosazadeh, Emran Habibi, Assie Jokar

    Background: Acne vulgaris adversely impacts quality of life, requiring safer alternatives to conventional treatments. This study explores a facial mask combining Bentonite's detoxifying and Alcea sulphurea 's anti‐inflammatory properties, rooted in Traditional Persian Medicine (TPM). It aims to evaluate its efficacy in reducing acne severity and enhancing patient satisfaction, integrating traditional and modern therapeutic approaches. Methods: This add‐on randomized, controlled clinical trial included 60 patients with moderate acne, recruited through purposive sampling in Sari from October 2022 to November 2023. Participants were randomly allocated into intervention (Bentonite‐Alcea mask + Azithromycin 250 mg) and placebo (placebo + Azithromycin 250 mg). Outcomes, including lesion count, acne severity, and satisfaction, were assessed at baseline, 4 weeks, and 8 weeks. Data analysis was conducted using SPSS version 16. Results: Sixty people completed the study (30 persons in both group). The mean and standard deviation of the age in control group was 24 ± 8.03 years and in placebo group was 19.03 ± 7.03 and 46 subjects (76.7%) were female. TLC and ASI in the fourth and eighth weeks in control group were significantly less than in placebo group ( p < 0.001). The percentage of relatively satisfied and very satisfied participants in the intervention group was significantly higher than the control group ( p < 0.001). Bentonite‐based facial mask with Alcea sulphurea extract had no serious side effects. The intervention group exhibited significant reductions in TLC (total lesion count) (55.45% ± 21.74%) and ASI (Acne Severity Index) (66.33% ± 27.15%) from baseline to 8 weeks ( p < 0.001), outperforming the placebo group. Patient satisfaction was notably higher in the intervention group, with 43.3% being very satisfied compared to 3.3% in the placebo group ( p < 0.001). Conclusion: A facial mask based on Bentonite and A. sulphurea extract effectively reduces acne severity and enhances patient satisfaction. These findings suggest its potential as a natural alternative or adjunct to conventional acne treatments. Trial Registration: Iranian registry: IRCT20220403054395N1

  • Open Access

    Innovative green niosomal piperlongumine as a novel topical treatment for dermatophytosis in guinea pigs model

    by Iman Haghani, Abbas Raeisabadi, Javad Akhtari, Aylar Arbabi, Mahdi Abastabar, Mohamad Taghi Hedayati, Zahra Yahyazadeh, Fereshteh Talebpour Amiri, Seyyed Mohammad Hassan Hashemi, Lotfollah Davoodi, et al.

    Dermatophytosis is a common superficial fungal infection that affects many people worldwide. Although various species of dermatophytes respond to common antifungal drugs, the recently identified Trichophyton indotineae isolates have exhibited significant terbinafine resistance due to mutations in the Squalene Epoxidase (SQLE) gene. Piperlongumine (PL), a natural alkaloid that stimulates ROS production and inhibits some crucial enzymes, has a good capacity to treat these fungal infections. As part of nanotechnology, niosomes can increase the success of the drug by targeting the affected areas. This study investigates the effectiveness of PL niosomal gel 1% in an infected animal model with T. indotineae, providing important insights for infection treatment. Thirty guinea pigs empirically infected with T. indotineae were divided into five groups (e.g., untreated control, treated groups with terbinafine 1%, niosome, PL gel 1%, and PL niosomal gel 1%) and subsequently scored both clinically and mycologically until the 38th day of inoculation. On the 38th day of the study, histological evaluation was performed. In contrast to the terbinafine group, which demonstrated no efficacy (P < 0.05), the 1% PL niosomal gel significantly decreased mycological and clinical lesion scores, leading to complete mycological cure (negative fungal cultures) by day 28. Moreover, histopathological analysis confirmed that this compound reduced epidermal thickness, fungal burden, and inflammation. However, it should be noted that the difference in recovery rate of pigs with PL gel 1% and PL niosomal gel 1% was not statistically significant (p = 0.6). Treatment of T. indotineae dermatophytosis using PL niosomal gel is a safer and more effective alternative to conventional topical and oral antifungal therapies. However, further studies are warranted to correlate these findings with clinical outcomes.


  • Open Access

    Green formulation of Menadione-loaded niosome as a skin-lightening preparation: In vitro/In vivo safety evaluation on Wistar rat

    by Majid Saeedi, Katayoun Morteza-Semnani, Jafar Akbari, Seyyed Mobin Rahimnia, Fatemeh Ahmadi, Mohammad Reza Mojaveri, Saghar Ahmadipour, Seyyed Mohammad Hassan Hashemi

    Purpose: In the present research, a green technique (an ultrasonic method) was used to synthesize menadione sodium bisulfite (MSB) niosome (Menasome) which is used to improve dermal delivery and increase anti-melanogenesis activities. Methods: Various cholesterol: surfactant (Chol: Sur) ratios were investigated to optimize the Menasomes. Photon correlation spectroscopy, attenuated total reflectance-Fourier transform infrared spectroscopy (ATR-FTIR), transmission electron microscopy (TEM), and differential scanning calorimetry (DSC) were employed to characterize the solid state of MSB in nanoparticle form. Additionally, the optimized formulation was used to investigate ex-vivo skin absorption, in vivo skin irritation, in vitro cell survival, and anti-melanogenesis activity. Results: The results exhibited that increasing cholesterol (Chol) declined the average size of the Menasomes from 653.766±25.171 nm to 298.133±8.823 nm and increased entrapment efficiency 30.237±3.4204% to 83.616±2.550 %. The rat skin permeation study indicated that Menasome gel administered more MSB in dermal layers (439.000±36.190μg/cm2 or 23.827±1.964%) than MSB plain gel (286.200± 22.6μg/cm2 or 15.53±1.227%). In both the in vivo skin irritation test and the in vitro cytotoxicity experiment, the extended-release behavior of the enhanced Menasome demonstrated a minimal side effect profile. Furthermore, optimum Menasome inhibited melanin formation (37.426± 1.644% at 15μM) greater than free MSB (57.383±1.654%) considerably (p <0.05). Furthermore, Menasome 7 prevented L-dopa auto-oxidation in higher levels (95.140±2.439%) than pure MSB solution (83.953±1.629%). Conclusion: According to the study's findings, the prepared Menasome could be employed as a viable nanovehicle for MSB dermal delivery, a promising solution for the management of human hyperpigmentation disorders.


  • Open Access

    Green Preparation, Characterization, Wound Healing Assessment, and Histopathological Evaluation of Vitamin A Encapsulated in Niosome and Solid Lipid Nanoparticle

    by Seyyed Mobin Rahimnia, Majid Saeedi, Katayoun Morteza-Semnani, Jafar Akbari, Maryam Ghasemi, Shidrokh Abootorabi, Reza Negarandeh, Mohammad Eghbali, Behrouz Jafarkhani, Mahshid Boskabadi, et al.

    Background: The purpose of the current work was to manufacture vitamin A (Vit A) niosome and solid lipid nanoparticle (SLN) using an ultrasonic approach and to evaluate its effect on wound healing. Methods: The nanoparticles were prepared through an ultrasonication technique and characterized by dynamic light scattering (DLS), and transmission electron microscopy (TEM). Further, the nanoparticles were evaluated for their various parameters such as pH, viscosity, spreadability, stability, in-vitro drug release study, in-vitro cytotoxicity, and in-vivo wound healing. Results: TEM confirmed the spherical nature of the Vit A-niosome and SLN. The Vit A formulations (niosome and SLN) were stable in the accelerated stability test (freeze-thaw cycle). Vit A release from the SLN gel and niosome gel was significantly higher (almost 70 and 80%, respectively) than simple Vit A gel. According to the animal study, the wound healing closure in the Vit A niosomal gel and Vit A SLN gel was greater than the other groups during the 21 days after surgery (P < 0.05) and was close to each other over time and on day 21. Based on histological data, wounds treated with Vit A niosome gel and Vit A-SLN gel had more collagen than the other groups. MDA malondialdehyde (MDA, an end-product of lipid peroxidation) significantly decreased in the Vit A-niosome and Vit A-SLN gel group after 21 days, while glutathione peroxidase (GPx), superoxide dismutase (SOD, an endogenous antioxidant), and hydroxyproline levels demonstrated an increase. Conclusion: The findings of this study revealed that the prepared Vit A nano-formulations could be used as a possible and safe nano-vesicle for Vit A cutaneous delivery thus potentially opening up new prospects for the treatment of wound disorders.


  • Open Access

    Green formulation of spironolactone loaded chitosan coated nano lipid carrier for treatment of acne vulgaris: a randomized double-blind clinical trial

    by Majid Saeedi, Katayoun Morteza-Semnani, Jafar Akbari, Zohreh Hajheydari, Amin Goodarzi, Seyyed Sohrab Rostamkalaei, Seyyed Mohammad Hassan Hashemi, Seyyed Mobin Rahimnia

    Purpose: Spironolactone (SPN), which is classified as an anti-androgen, has demonstrated efficacy in treating acne. This study aimed to utilize ultrasonication to create a chitosan-coated nano lipid carrier (NLC) for enhancing the delivery of SPN to the skin and treating acne. Methods: Various Hydrophilic-Lipophilic Balance (HLB) values were investigated to optimize the SPN-NLCs. Photon correlation spectroscopy, attenuated total reflectance-Fourier transform infrared spectroscopy (ATR-FTIR), transmission electron microscopy (TEM), and differential scanning calorimetry (DSC) were employed to characterize the solid state of SPN in nanoparticle form. Additionally, the optimized formulation was used in a double-blind, randomized clinical trial. Results: Reducing the HLB of the surfactant mixtures resulted in a reduction in the size of SPN-NLCs. The formula with the smallest particle diameter (238.4±0.74 nm) and the lowest HLB value (9.65) exhibited the highest encapsulation efficiency of 79.88 ± 1.807%. Coating the optimized SPN-NLC with chitosan increased the diameter, PDI, zeta potential, and encapsulation efficiency. In vitro skin absorption studies demonstrated sustained release profiles for chitosan-coated SPN-NLC. In the double-blind trial, a gel containing chitosan-coated SPN-NLC effectively treated mild to moderate acne vulgaris, leading to improved healing and reduced lesion count after 8 weeks of therapy compared to the placebo. It successfully addressed both non-inflammatory and inflammatory lesions without adverse effects on the skin. Conclusion: The findings indicate that chitosan-coated SPN-NLCs have the potential as nanoparticles for targeted SPN delivery to the skin, offering novel options for the treatment of acne vulgaris.